<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02131220</url>
  </required_header>
  <id_info>
    <org_study_id>Zhongshan 2012-134</org_study_id>
    <nct_id>NCT02131220</nct_id>
  </id_info>
  <brief_title>Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction</brief_title>
  <acronym>ERUPTION</acronym>
  <official_title>A Randomized, Parallel-controlled, Multi-center Study of the Effects of Intracoronary Recombinant HUman Prourokinase or TIrofiban on the Coronary Flow During Primary PCI for the Acute Myocardial InfartiON</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether intracoronary selective thrombolysis are
      more effective than tirofiban on the coronary flow during primary percutaneous coronary
      intervention for the acute myocardial infarction.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary flow using corrected Thrombolysis In Myocardial Infarction Frame Count (cTFC)</measure>
    <time_frame>At the end of Percutaneous Coronary Intervention procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ST segment resolution in ECG</measure>
    <time_frame>3 hours post PCI procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peak troponin T level</measure>
    <time_frame>in the 7 days post PCI procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma N terminal-proBNP levels</measure>
    <time_frame>1 and 30 days post PCI procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>infarction area confirmed by SPECT</measure>
    <time_frame>30 days post PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of major adverse cardiac events (MACE) defined as the composite of death, myocardial infarction and target vessel revascularization</measure>
    <time_frame>30 days post PCI</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>TIMI defined total major bleeding</measure>
    <time_frame>30 days post PCI</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <condition>Thrombolytic Therapy</condition>
  <arm_group>
    <arm_group_label>Prourokinase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intracoronary bolus infusion of 20mg prourokinase using selective catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirofiban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intracoronary tirofiban bolus infusion using selective catheter (10ug/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intracoronary saline bolus infusion using selective catheter (20ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prourokinase</intervention_name>
    <description>20mg intracoronary bolus infusion using selective catheter during PCI</description>
    <arm_group_label>Prourokinase</arm_group_label>
    <other_name>Reocmbinant Human Prourokinase for Injection</other_name>
    <other_name>TIANJIN TASLY PHARMACEUTICAL CO.,LTD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirofiban</intervention_name>
    <description>10ug/kg intracoronary bolus infusion using selective catheter during PCI</description>
    <arm_group_label>Tirofiban</arm_group_label>
    <other_name>Grand Pharmr (China) Co. Ltd</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>intracoronary bolus infusion using selective catheter during PCI</description>
    <arm_group_label>Normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ST-segment elevation AMI within 12 hours of symptom onset

        Exclusion Criteria:

          -  Contraindications to thrombolysis or PCI

          -  Patients administered a fibrinolytic agent before PCI

          -  Patients enrolled in clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junbo Ge, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Zhongshan Hospital, Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong Huang, M.D.</last_name>
    <phone>862113512142875</phone>
    <email>huang.dong@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Cardiology, Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Huang, M.D.</last_name>
      <phone>862113512142875</phone>
      <email>huang.dong@zs-hospital.sh.cn</email>
    </contact>
    <investigator>
      <last_name>Dong Huang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2014</study_first_submitted>
  <study_first_submitted_qc>May 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2014</study_first_posted>
  <last_update_submitted>July 29, 2017</last_update_submitted>
  <last_update_submitted_qc>July 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Ge Junbo</investigator_full_name>
    <investigator_title>Director, Dept. of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital</investigator_title>
  </responsible_party>
  <keyword>No-Reflow Phenomenon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tirofiban</mesh_term>
    <mesh_term>Saruplase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

